Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock.

President Trump on Wednesday signaled his support for NATO’s mutual defense pact after previously casting doubt on whether he would abide by it. “I stand with it. That’s why I&#82… ...

Since launching in 1934, The Investment Company of America fund has rolled with World Wars and evolving economies. These are its stock picks.

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

The Detroit Pistons have "significant mutual interest" in making a big offseason move with this free agent sharpshooter.

Defence sector mutual funds have delivered impressive returns in 2025, driven by India’s push for self-reliance in defence manufacturing. These high-risk funds offer a unique opportunity for ...

Let's take an example, a mutual fund was priced (NAV) at Rs 100 one year back and fund gave 20% returns in last 1 year. Now for the growth option, today's mutual fund price (NAV) will be 120, so ...

AQR Capital Management is doubling down on a strategy that seeks to juice returns with leverage for its first new US mutual funds in four years.] The Greenwich, Connecticut-based quant pioneer ...

Review which funds and institutions currently hold Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock for ownership information.

NATO commits to higher spending sought by Trump and mutual defense While Trump got what he wanted at the brief NATO summit, his allies will be relieved he committed to the fundamental principle of ...